학술논문
Enzalutamide combination treatment (tx) suspension in men with high-risk biochemically recurrent (BCR) prostate cancer: Outcomes from EMBARK.
Document Type
Article
Author
Source
Journal of Clinical Oncology; 2024 Supplement 4, Vol. 42, p156-156, 235p
Subject
Language
ISSN
0732183X